Related Experiment Video

Updated: Jul 18, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

[New medications; erlotinib]

A F Cohen1, E A Dubois, H van Bronswijk

  • 1Centre for Human Drug Research, Zernikedreef 10, 2333 CL Leiden. ac@chdr.nl

Nederlands Tijdschrift Voor Geneeskunde
|December 30, 2006
PubMed

Insights

Erlotinib targets the epidermal growth-factor receptor (EGFR) to halt cancer cell growth. This targeted therapy is used for advanced non-small-cell lung cancer when other treatments fail.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Context:

  • Non-small-cell lung cancer (NSCLC) is a leading cause of cancer-related mortality.
  • Epidermal growth-factor receptor (EGFR) signaling pathways are implicated in NSCLC progression.
  • Resistance to traditional chemotherapy necessitates novel therapeutic strategies.

Purpose:

  • To investigate the efficacy of Erlotinib as a targeted therapy for advanced NSCLC.
  • To elucidate the mechanism of action of Erlotinib in inhibiting EGFR phosphorylation and downstream signaling.
  • To evaluate Erlotinib's role in patients who have progressed on prior cytotoxic chemotherapy.

Summary:

  • Erlotinib functions as a tyrosine kinase inhibitor, specifically targeting the EGFR/HER1 pathway.
  • By inhibiting EGFR phosphorylation, Erlotinib disrupts critical signal transduction cascades.
  • This disruption leads to reduced cancer cell proliferation and increased apoptosis, offering a therapeutic benefit.

Impact:

  • Erlotinib provides a targeted treatment option for advanced NSCLC patients with unmet needs.
  • The drug's mechanism offers a molecularly targeted approach to cancer therapy.
  • Clinical application of Erlotinib can improve patient outcomes in specific NSCLC populations.

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...